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Molecular engineering to increase the percentage identity to common human immuno-
globulin sequences of non-human therapeutic antibodies and scaffolds has become 
standard practice. This strategy is often used to reduce undesirable immunogenic 
responses, accelerating the clinical development of candidate domains. The first human-
ized shark variable domain (VNAR) was reported by Kovalenko and colleagues and used 
the anti-human serum albumin (HSA) domain, clone E06, as a model to construct a 
number of humanized versions including huE06v1.10. This study extends this work by 
using huE06v1.10 as a template to isolate domains with improved biophysical proper-
ties and reduced antigenicity. Random mutagenesis was conducted on huE06v1.10 
followed by refinement of clones through an off-rate ranking-based selection on target 
antigen. Many of these next-generation binders retained high affinity for target, together 
with good species cross-reactivity. Lead domains were assessed for any tendency to 
dimerize, tolerance to N- and C-terminal fusions, affinity, stability, and relative antigenicity 
in human dendritic cell assays. Functionality of candidate clones was verified in  vivo 
through the extension of serum half-life in a typical drug format. From these analyses the 
domain, BA11, exhibited negligible antigenicity, high stability and high affinity for mouse, 
rat, and HSA. When these attributes were combined with demonstrable functionality in a 
rat model of PK, the BA11 clone was established as our clinical candidate.
Keywords: Vnar, soloMer, single chain binding domain, shark, humanization, half-life extension, 
pharmacokinetics
inTrODUcTiOn
In recent years, different approaches such as complementarity-determining region (CDR) grafting, 
framework-homology-based, germline-homology-based re-surfacing, and epitope depletion have 
been adopted to reduce potential immunogenic responses from non-human therapeutic biologics 
(1–5). According to Reichert (6), of the 52 antibodies in late stage clinical trials in Europe and the 
Abbreviations: IgNAR, immunoglobulin new antigen receptor; VNAR, variable domain of shark new antigen receptor; CDR, 
complementarity-determining region; FW, framework HV, hypervariable region; PK, pharmacokinetics; HSA, human serum 
albumin.
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US, the majority, 43, are humanized or are fully human exem-
plifying the success and clinical validation of these processes. 
Furthermore, the six monoclonal antibodies (mAbs) approved 
for use in the European Union or the US in 2016, three were 
humanized, two were fully human, and one was a chimeric IgG1 
with a further 10 human or humanized antibodies in review (6). 
Of those mAbs approved for therapeutic use, three are the block-
buster drugs for oncological indications, Rituximab (Rituxan), 
Trastuzumab (Herceptin), and Bevacizumab (Avastin), each of 
which generated in excess of $6 billion in revenues in 2015 (7–9).
The development of next-generation therapeutic biologics 
has been gaining pace with over 50 products based on both 
immunoglobulin and non-immunoglobulin scaffolds at varying 
stages of development (6, 10). Much of this development reflects 
the drive to overcome the limitations of classical antibodies such 
as their complex structure, and large size resulting in high cost 
of manufacture from an economic perspective and limited tissue 
penetration from a biological perspective (11–14). The focus of 
this study was the improvement of the biophysical properties of a 
humanized VNAR, which is the variable binding antigen specific 
domain derived from the new immunoglobulin antigen receptor 
or IgNAR (15). As IgNAR forms an integral part of the adaptive 
immune system of sharks, high-affinity, highly selective IgNARs 
can be raised through immunization and target-specific VNAR 
domains selected through classic phage display technology 
(16–18). Although demonstrating the target-specific attributes of 
antibodies, VNARs do not originate from an immunoglobulin 
lineage but are postulated to have evolved from cell surface mem-
bers of the Ig superfamily such as ICAMs and VCAMs (19–21). 
Interestingly, their sequence identity is closer to human light 
chain frameworks than heavy chains. As with other non-human 
sources of antibodies, this reduced relatedness to human mAbs 
is the driving force behind developing a humanization strategy 
for the development of these domains for clinical use. Elasmogen 
Ltd. has a proven, patented methodology for the humanization 
of VNAR domains, the endpoint of which are therapeutic clinical 
candidates known as soloMERs™ (22).
The subject of this work, hE06v1.10, is a humanized version of 
an anti-HSA clone called E06 that was originally isolated from an 
immunized dogfish (18, 23). E06 can be fused with many different 
therapeutic partners including but not limited to, VNAR domains, 
scFvs, peptides, and proteins to increase their systemic half-life 
and subsequent therapeutic window (23). With broad utility 
across multiple indications, the biophysical properties of the final 
humanized version of E06 were critical to negate any downstream 
production issues with aggregation or potential immunogenicity. 
The first steps toward humanization of VNAR domains were 
conducted by Kovalenko et al. (24) using the anti-hen egg (HEL) 
domain, 5A7 (16), as a model template. Given the evolutionary 
distance between VNARs and true IgGs, the foundation of the 
approach was based primarily on structural similarity to human 
framework scaffolds. Using this strategy, DPK9 was selected. The 
underlying methodology used to successfully humanize 5A7 was 
then transposed onto the anti-human serum albumin (HSA) 
binding VNAR domain, E06 resulting in the construction of 
v1.10. A second version of humanized E06, v2.4, was designed 
based on human Kappa germline framework DPK24.
This work has studied v1.10 and v2.4 in more depth and has 
revealed a propensity for the v1.10 domains to dimerize and in 
the case of v2.4 to bind to HSA with lower affinity, questioning 
their applicability for clinical development. To overcome the 
unfavorable characteristics of v1.10 and v2.4, these were used as 
templates for mutagenesis to select better performing humanized 
versions of these proteins.
MaTerials anD MeThODs
random Mutagenesis of e06v1.10 and 
e06v2.4
E06v1.10 and E06v2.4 sequences were cloned into the phage dis-
play vector pWRIL-9 and tested as periprep extracts for binding 
to cognate target and relevant controls. This vector is comparable 
to pWRIL-1 (25) with the c-Myc tag replaced by an HA tag, 
and the leader sequence is derived from pelB. Sequences were 
mutagenized by error-prone PCR to deliver up to 9 substitutions/
VNAR sequence using a GeneMorph II random mutagenesis kit 
(Agilent Technologies, Santa Clara, CA, USA). Libraries were 
cloned into pWRIL-9 and transformed into TG1 electrocompe-
tent cells (Lucigen, Middleton, WI, USA). Library diversity was 
analyzed by sequencing over 100 clones from each repertoire.
selection from libraries by Phage Display
Libraries were rescued and selected twice using Nunc Maxisorp 
immunotubes as previously described (26). For the first round of 
panning, tubes were washed five times with PBS containing 0.1% 
Tween 20 (PBS-T) and five times with PBS; for pan 2, the number 
of washes with and without Tween 20 was doubled. Following 
each round of panning, two 96-well plates of individual colonies 
were picked with a QPix2 XT (Genetix, San Jose, CA, USA) and 
grown for periplasmic protein extraction. Binding to HSA (and 
HEL control) was evaluated by ELISA using 50% of the crude 
periplasmic protein extract (27). VNARs were detected via their 
HA tag using a high-affinity mAb HRP conjugate (clone 3F10; 
Roche, Basel, Switzerland). All samples were processed with a 
Perkin Elmer MiniTrak robotic liquid handling system (Waltham, 
MA, USA).
reformatting to eukaryotic expression 
Vector and analysis of Output by elisa
Unique clones showing OD450 by periprep ELISA at least 25% 
higher than the readings obtained from parental huE06v1.10 or 
v2.4 were selected for batch conversion into the proprietary mam-
malian expression vector pSMED2. Equal amounts of pWRIL-9 
plasmid DNA from clones were pooled, and VNAR sequences 
were amplified by PCR with primers inserting BssHII and EcoRI 
at the 5′ and 3′ ends, respectively. After cloning and transforma-
tion of Escherichia coli TG1 electrocompetent cells, a fourfold 
over-representation of the starting number of clones was grown 
in 96-deepwell culture plates (Greiner Bio One, Frickenhausen, 
Germany) and plasmid DNA purified using a QIAprep 96 Turbo 
BioRobot Kit in a BioRobot 8000 (Qiagen, Hilden, Germany). In 
a 96-well plate format, each clone was expressed transiently in 
200 µL of HEK293 cells previously adjusted to a density of 106/mL. 
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Each 200  µL culture was transfected with 200  ng of plasmid 
DNA using lipofectamine (Invitrogen, Carlsbad, CA, USA) and 
grown at 37°C and 8% CO2 while shaking at 250 rpm to maintain 
cells in suspension. After 24  h, cultures were supplemented 
with tryptone to a final concentration of 0.5% and expression 
continued for 6 days. Post-expression media samples from HEK 
293 transfections were tested for binding to HSA and HEL by 
ELISA. Detection was achieved via an anti-6-His HRP conjugate 
(ab1187; Abcam, Cambridge, UK).
Off-rate selection screening
Samples of the “best-performing” media from the small scale 
HEK293 transfections were subject to kinetic analysis using a 
T200 BIAcore instrument for off-rate ranking (28) (GE Healthcare 
Life Sciences, Little Chalfont, UK). For off-rate screening sam-
ples were diluted 1:5, 0.2 μm-filtered, then filtrates run over a 
research-grade carboxy-methyl-dextran chip (CM5) onto which 
HSA was immobilized using standard amine coupling chemistry. 
The association phase for all samples was 2  min, and the dis-
sociation was monitored for 3 min at a flow rate of 100 µL/min, 
followed by two 10 µL injections of glycine pH 1.5 at a flow rate of 
100 μL/min. All binding experiments were performed at 25°C in 
HBS/EP buffer. Analysis of the resultant sensorgrams made use of 
the 1:1 global Langmuir binding model. Those samples showing 
the slowest dissociation rates were then selected for larger-scale 
protein production and DNA sequences of VNARs determined.
elisa assay and ec50 Determination
Rat, mouse, and HSAs used in ELISA-binding assays were from 
Sigma-Aldrich. For direct ELISA formats Nunc Maxisorp 96-well 
plates were coated at 1 µg/mL antigen in PBS and then blocked 
with 4% non-fat milk in PBS. Purified 6-his-tagged control and 
humanized VNAR proteins in PBS were diluted 1/3 into wells and 
double-diluted further across the plate. After incubation for 1 h, 
plates were washed three times with 0.05% Tween 20 in PBS. The 
detection of antigen bound VNARs was achieved by incubation 
with an anti-6-His HRP mAb for 1 h or where appropriate with 
an anti HA tag mAb HRP conjugate (clone 3F10; Roche) and 
developed by adding TMB substrate. When fully developed, the 
reactions were halted by the addition of 1 M H2SO4 absorbance 
measured at 450 nM. Data were processed using SigmaPlot 9.
affinity Measurements
Affinities of selected clones were determined on a T200 BIAcore 
surface plasmon resonance instrument essentially as described 
previously (24). As well as measuring affinity for HSA, the mutated 
anti-HSA VNARs were also assessed for binding to mouse serum 
albumin (MSA) and rat serum albumin (RSA). A CM5 chip was 
prepared in which the first flow cell was used as a reference to 
correct for bulk refractive index, matrix effects, and non-specific 
binding. Approximately 300 RU of HSA was immobilized onto 
flow cell 2, 350 RU of MSA was immobilized onto flow cell 3, 
and 600 RU of RSA onto flow cell 4. Prior to immobilization, 
the serum albumins were made up in 10  mM sodium acetate 
buffer (pH 4.5) and post-coupling the remaining activated groups 
was blocked with 1.0 M ethanolamine-HCl pH 8.5. For affinity 
measurements, purified anti-HSA VNAR monomers, dimers, 
and trimers were diluted to 1.56–100 nM in HBS/EP buffer and 
injected over the chip as above. Analysis of the resultant sensor-
grams was performed using the 1:1 global Langmuir binding 
model fit analysis (BIAcore Evaluation Software).
Protein expression and Purification
Expression of VNAR proteins for periprep screening and phage 
ELISA was carried out as described (29). For small-scale transient 
expression and off-rate screening, mutated VNAR genes were 
cloned into pSMED2 vector containing a CMV promoter and 
a C-terminal 6-His tag. Following off-rate screening plasmid 
preparations of selected clones were scaled up and used for 1 L 
PEI-mediated transfection and transient expression in HEK293 
host cells (30, 31) using serum free FreeStyle™ 293 media 
(Invitrogen). Purification of expressed protein was achieved by 
immobilized metal chelate chromatography using Ni2+ charged 
resin followed by cation exchange chromatography with buffer 
exchange as appropriate between steps. Final protein samples 
were buffer exchanged to PBS and stored frozen at −20°C. If 
required, proteins were then subjected to a final polishing step 
by preparative size-exclusion chromatography using a Superdex 
200 26/60 size-exclusion column equilibrated with PBS. Eluted 
peaks from this chromatography were pooled, then concentrated 
using Amicon Ultra filtration units. Protein concentrations were 
determined by UV spectroscopy. Expression levels of VNAR 
proteins were generally in the region of 0.5–3  mg/L, and elec-
trophoretic analysis of protein samples was performed on 12% 
NuPAGE BisTris gels using a MOPS buffer system (Invitrogen). 
Analytical size-exclusion chromatography was performed 
using an Agilent 1200 series HPLC system and ZORBAX GF 
250 9.4  mm ×  250  mm 4  μm column or TSK gel G3000PW 
7.5 mm × 30 mm column equilibrated with phosphate-buffered 
saline at pH 7.4 with instrument set up and run parameters 
adjusted as required for each run.
cloning of Vnar Dimeric and Trimeric 
constructs
VNAR E06 and lead humanized clones BA11, BB11, and BB10 
were selected as the backbone of several dimeric and trimeric 
fusion protein constructs. Dimers were assembled using a stand-
ard PCR overlapping extension techniques joining the albumin 
binding domain, via a (GGGGS)4GAHS flexible linker to the 
carboxyl or amino terminal end of a control and naive VNAR 
domain known as 2V. The trimeric constructs were made by 
flanking the albumin binding domain with the same naive 2V 
domain at both terminal ends (23). Constructs were cloned into 
pSMED2, plasmid preparation scaled up and the resultant DNA 
used to transiently express protein in HEK 293 cells (30, 31).
Dendritic cell–T-cell (Dc–T) assay
A DC–T proliferation assay was used to identify the presence 
or absence of possible T-cell epitopes within the wild-type 
E06 and humanized variants 2G, BA11, BB11 and BB10 (per-
formed at ProImmune Ltd., UK using ProImmune’s REVEAL® 
Immunogenicity System DC–T  cell assay). For this study, test 
proteins and controls were incubated with CD8+ T-cell-depleted 
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peripheral blood mononuclear cells (PBMCs) prepared for 
7 days, from a panel of 20 different healthy human donors. Each 
PBMC sample was HLA-typed and donors were selected (by 
DRB1 allotyping) to approximately represent MHC class II allele 
frequency distributions across the global population.
In brief, adherent donor PBMCs were cultured with appro-
priate growth factors to generate monocyte-derived DCs. DCs 
were then loaded with either test or control antigen protein or 
left untreated. Test proteins were loaded at a final concentration 
of ~0.34 μM (5 µg/mL). Mature antigen-loaded DCs were then 
co-cultured (at a set ratio) with autologous CFSE-labeled T cells 
in multi-well plates. Each test condition was set up in octuplet 
and incubated for 7 days. Positive control antigens used for this 
assay were Tuberculin purified protein derivative (PPD from 
Mycobacterium) at a final assay concentration of 0.2–0.4  µM 
(~5 μg/mL) (70–100% of donors are expected to react to this 
protein as a result of previous vaccination, through a memory 
immune response). A second control antigen used, keyhole limpet 
hemocyanin (KLH) is a known potent naive protein immunogen. 
This was used at ~0.64 μM (0.25 mg/mL) in the assay (up to 70% 
of donor samples might be expected to react to this protein, 
driven by a naive immune response). At the end of the incubation 
period, cell samples were stained with anti-CD4 antibody, then 
washed and fixed for flow cytometric analysis. Proliferation was 
determined by measuring a decrease in CFSE intensity.
Pharmacokinetic (PK) studies
Three groups of four male Sprague Dawley rats received a single 
intravenous (bolus) administration of 2V-E06-2V, 2V-BA11-2V, 
or 2V-BB11-2V dosing at 1 mg/kg. Blood samples (0.3 mL) were 
collected into tubes containing Lithium Heparin as an antico-
agulant before dosing and at the following times: 30 min and 4, 
12, 24, 48, 84, 96 120, and 144 h. These were placed on ice and 
plasma collected from each after centrifugation at 3,000 × g, at 
4°C for 10 min. Prior to analysis plasma samples were stored 
at −80°C.
lc–Ms/Ms Methodology for the 
Bioanalysis of PK samples
A quantitative LC–MS/MS method had been previously developed 
to specifically measure concentrations of 2V-E06 in rat plasma 
(23). In summary, the method utilizes the C-terminal 6x His tag 
present on these proteins molecules to provide sample enrich-
ment using a magnetic Ni-NTA bead capture step. Following 
analyte enrichment and tryptic digestion of the sample, targeted 
LC–MS/MS is used to quantify specific signature peptides in 
all parts of 2V and the humanized E06 domains. Signature 
peptides within each partner were identified by in silico tryptic 
digestion. For E06 and humanized variants BA11 and BB11, the 
signature peptide EQISISGR was selected and AQSLAISTR for 
2V. Control signature peptides and a labeled internal standard 
peptide EQI-[U13C3, 15N-Ser]-ISGRAQS-[U13C6, 15N-Leu]-
AISTRHHHHHH were synthesized (by Cambridge Research 
Biochemicals, Billingham, UK). Assessment of peptides allowed 
the PK determination of the VNARs (serum half-life) as well as 
monitoring of (GGGGS)4GAHS linker stability.
Plasma Pull Down and Trypsin Digestion
VNAR 2V-E06-2V protein was diluted into heparinized rat 
plasma at 30, 20, 10, 5, 3, 1, 0.3, 0.2, and 0.01 µg/mL. A total of 
10 µL of each dilution was added to 40 µL of 0.1 M phosphate 
buffer pH 8 followed by 50 µL of 6 M guanidine hydrochloride 
containing 1 µg/mL of the heavy isotope labeled internal standard 
peptide EQI-[U13C3,15N-Ser]-ISGRAQS-[U13C6,15N-Leu]-
AISTRHHHHHH. After mixing, these samples were each 
reduced and alkylated as previously described (23). For the PK 
sampling time points, 10  µL of plasma was added to 40  µL of 
0.1 M phosphate buffer pH 8. The samples were then diluted by 
the addition of 100 µL 100 mM phosphate, pH 8, 0.1% CHAPS 
in preparation for sample enrichment. Sample enrichment and 
magnetic bead processing was performed in 1.5 mL capped tubes 
and magnetic capture blocks. Twenty-five microliters Ni2+-NTA 
magnetic beads plus 75  µL 100  mM phosphate, pH 8, 0.1% 
CHAPS were added to each sample. After mixing, the magnetic 
beads were trapped by magnetic block and the fluid containing 
the unbound proteins was removed. The beads were washed three 
times with 500 µL 100 mM phosphate, pH 8, 0.1% CHAPS with 
magnetic immobilization of beads between each wash before a 
final 500 µL wash with 100 mM phosphate, pH 8, 0.1% CHAPS 
containing 20  mM imidazole. Bound proteins were eluted in 
100 µL of 0.5 M Imidazole, 10 mM CaCl2, 50 mM Tris HCl, pH 8. 
Eluted protein samples were then trypsin digested by addition 
of 20 µL of proteomics grade trypsin (made up at 20 µg/mL in 
10 mM CaCl2, 50 mM Tris HCl, pH 8) followed by incubation at 
37°C for 18 h prior to LC–MS/MS analysis.
lc–Ms/Ms analysis
The samples were loaded into the auto-sampler module of a 
Waters Acquity UPLC (chilled at 6°C) and 5 µL of the extracted 
samples injected onto the LC–MS/MS system. The native and 
stable-labeled signature peptides were separated on Acquity UPLC 
BEH C18 1.7  µm 2.1  mm ×  50  mm column equilibrated with 
solvent A water/acetonitrile/formic acid (95/5/0.1) and eluted 
with a stepped gradient as follows. At a flow rate of 0.5 mL/min, 
the column was washed with buffer A for 4  min, then from 4 
to 8 min buffer was changed by gradient mixing to 20% solvent 
B +  100% acetonitrile +  0.1% formic acid. From 8 to 8.5  min 
solvent B increased to 55% then back to 45% solvent B at 9 min 
and back to 100% solvent A at 10  min in preparation for the 
next sample injection. Chromatography runs were carried out 
at ambient temperature, and under these conditions, the reten-
tion time for the analytical and reference peptides was 6.11 min 
for EQISISGR and 6.27  minutes for AQSLAISTR (±0.5  min). 
The peptide analytes EQISISGR and AQSLAISTR and control 
internal standard labeled peptides were detected by atmospheric 
pressure electrospray ionization MS/MS using a Xevo TQS MS/
MS detector. The analytical column eluate was delivered into the 
source operated at an IonSpray voltage of 3,300 eV with settings 
as follows: cone (V) 25, source offset (V) 45, source temperature 
150°C, desolvation temperature (600°C), cone gas flow (L/h) 0, 
desolvation gas flow (mL/min) 0, collision gas flow (mL/min) 
0.15, and nebulizer gas flow (Bar) 7.00.
For the analytes and control labeled internal standard peptides, 
MRM transitions were 445.2–519.3 for EQISISGR, 473.8–747.4 
FigUre 1 | Mutated library design, QC and outputs. (a) Amino acid sequence alignment of humanized E06 v1.10 and E06 v2.4 with wild-type E06. FW is 
framework region; CDR is complementarity-determining region; HV is hypervariable region. (B) Phage-binding ELISA to human serum albumin (HSA) and hen egg 
white lysozyme (HEL)-coated plates. Phage displaying VNAR domains E06, humanized E06 v1.10 and humanized E06 v2.4, and a negative control clone 5A7. 
Control 5A7 is a hen HEL-binding VNAR. (c) Selection of mutated clones based on periprep ELISA binding to HSA. A total of 37 humanized E06v1.10 (boxed) and 
12 humanized E06 v2.4 clones (circled) clones were identified for further studies. Criterion for selection was an OD450 (after 5 min development time) of at least 
100% of the signal generated by parental humanized E06 v1.10 and E06 v2.4 controls assayed under the same conditions.
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for AQSLAISTR, 447.2–523.3 for EQISISGR-IS, and 477.3–754.4 
for AQSLAISTR-IS. In all experimental runs, a system suitability 
test was performed by the injection of a 50 µg/mL AQSLAISTR 
and EQISISGR mixed standard in buffer. The ion chromatograms 
were quantified by reference to standard curves spiked into fresh 
control plasma and analyzed over the range 0.01–30 µg/mL and 
a calibration curve constructed by plotting the peak area ratio 
of the calibration standards vs. the concentration of peptide 
fragments in a control matrix and determine the linear regres-
sion parameters of the curve, using a 1/x2 weighting factor. The 
concentration of peptide fragments in the quality control and test 
samples were determined by interpolation of the peak area ratios 
from the calibration curve.
stability assay
The stability of VNAR E06 and humanized E06 BA11 was assessed 
after exposure to extremes of temperature and pH. Samples of E06 
and humanized E06 BA11 proteins were prepared at 10 µg/mL 
working concentration and placed on a 100°C preheated block. 
Samples were withdrawn from experimental conditions at 0, 5, 
10, 20, 30, 40, 50, and 60 min time points and transferred into 
wells containing appropriate volume of PBS pH 7.4 to obtain a 
final concentration of 0.5 µg/mL. Boiled samples recovered in PBS 
were kept on ice for 1 h before assessing VNAR E06 and human-
ized VNAR BA11 in an has-binding ELISA. In a similar assay 
the pH stability of VNAR domains was assessed. Samples were 
prepared and incubated at a working concentration of 10 µg/mL 
in a final volume of 50 µL at the designated pH value. For acidic 
conditions, pHs 1.5, 3, and 5.5 protein samples in PBS pH 7.4 
were adjusted using 1 M HCl or 0.1 M citric acid and for basic 
pHs 8.5, 10 and 11 samples in PBS were titrated to required pH 
value using borax buffer or 1 M NaOH. Samples were incubated 
at room temperature, and aliquots withdrawn at stipulated time 
points and neutralized in PBS pH 7.4 to a final concentration of 
0.5 µg/mL. Samples were incubated at designated pH values for 
up to 28 days, and the HSA-binding activity of the treated samples 
was determined using ELISA.
resUlTs
affinity Maturation of humanized Vnars 
by random Mutagenesis, library 
screening and selection
Analysis of E06 clones humanized (hE06) by targeted insertion of 
residues and sequences from human V Kappa germ lines led to 
two “parental” molecules (v1.10 and v2.4 Figure 1A) with specific 
but lower binding affinities and undesirable biophysical proper-
ties (Figures 1 and 2 respectively). In order to make improve-
ments to these two humanized variants, two randomly mutated 
libraries were constructed by error-prone PCR using DNA from 
these clones as the initial template (v1.10 and v2.4 Figure  1A, 
based on DPK9 and DPK24 human Kappa germline sequences, 
respectively). To ensure full coverage of the hE06 sequences and 
to reap any potential benefits of multiple substitutions in the pro-
tein sequences, conditions were optimized to deliver a maximum 
of nine nucleotide mutations per VNAR. Phagemid libraries of 
~5 × 107 clones for both hE06v1.10 and v2.4 were constructed 
FigUre 2 | SDS PAGE and SEC profiles of native E06 and humanized E06 v1.10. (a) SDS PAGE and Coomassie blue staining of 2 µg of wild-type E06 and E06 
humanized v1.10 proteins. Lane 1, E06; Lane 2, E06 v1.10; Lane M, molecular weight markers. (B) Analytical SEC chromatogram of wild-type E06 protein.  
(c) Analytical SEC chromatogram of humanized E06 v1.10 protein.
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and diversity determined by randomly selecting and sequencing 
of over 100 individual clones from each library. Results indicated 
a good coverage of mutations along the full sequence length, with 
an overall mutation rate of ~90% (90/103 and 94/103 clones had 
a changed amino acid residue, for hE06v1.10 and v2.4, libraries 
respectively).
In order to recover molecules with improved binding proper-
ties two rounds of phage display selection were performed using 
HSA as a target. Approximately 200 individual clones were 
randomly picked from each library and round of panning (total 
of 800 clones) and tested for binding by ELISA using VNAR pro-
tein derived from crude periplasmic extracts. Additional control 
screening was performed using non target antigens (HEL and 
blocking agent) to confirm that there was no overall gross VNAR 
misfolding leading to polyreactivity or non-specific stickiness. 
An initial examination of the sequences of the enriched clones 
did not offer up a clear pattern or any obvious positional bias 
but placed the mutations randomly throughout the parental 
templates. In addition, parental hE06v1.10 was recovered a total 
of 53 times from pan 1 and 80 times from pan 2, while hE06v2.4 
was observed only once in pan 2 and did not occur in the pan 1 
sequences at all. The remaining “new” clones were subjected to 
further analysis including their expressability and any propen-
sity to form dimers (results not shown). Figure  1C shows the 
isolation of a final panel of mutated clones based on periprep 
ELISA binding from which 37 humanized E06v1.10 (boxed) 
and 12 humanized E06v2.4 clones (circled) were selected for 
further characterization. These 49 clones were transferred to a 
eukaryotic expression vector and small scale transient expres-
sions performed in HEK 293 cells.
Protein expression, assessment, and 
characterization
Media samples from HEK 293 expressions were screened for 
specificity using an HSA-binding ELISA and off-rate ranking was 
performed on the same samples using a T200 BIAcore surface 
plasmon resonance instrument. Clones that showed a slow-off 
rate nearing that of parental E06 and were positive by ELISA, 
giving signals similar to the parental hE06v1.10 or v2.4 clones, 
and were selected for further study (Figure 3A). The sequences of 
these selected clones were determined and those from v1.10 and 
v2.4 derived libraries are shown in Figures  3B,C, respectively. 
The positions of the mutations identified, even in this focused 
sub-panel of lead clones, were typically one or two amino acid 
mutations randomly located along the length of the VNAR pro-
teins (Figures 3B,C).
Transient expression of these 15 lead clones was scaled up in 
HEK 293 cells to produce proteins for further study. After scale up 
and growth in serum free media and post-purification, expression 
levels of between 3 and 10 mg/L were obtained for the humanized 
monomeric, dimeric, and trimeric constructs. Purified protein 
samples were quantified by UV spectroscopy and concentrations 
determined. For the best expressing clones, together with suitable 
controls (E06 wild-type, v1.10, AH7, AD4, AG11, BA11, BB11, 
BB10, and v2.4 derived clones 1H, 2G, 5F, 8C, and 8D), ranking 
of the purified proteins was determined by ELISA (Figures 4A,B) 
and EC50 values calculated using SigmaPlot 9.0 (Figures 4C,D). 
Based on expression levels and EC50 values, a final panel four 
of clones was selected. From the mutated v1.10 library BB10, 
BA11, and BB11 and from the v2.4 derived library, clone 2G was 
characterized in more detail.
FigUre 3 | ELISA and off-rate screening analysis of related and humanized mutant. The intensity of binding of media samples from small scale transient 
expressions in HEK 293 cells were screened and compared by kinetic off-rate analysis, using a T200 BIAcore instrument, and HSA-binding ELISA. (a) Selected lead 
clones derived from v1.10 library (data for v2.4 selection not shown). Off-rate as a percentage of the parental E06 off-rate plotted together with ELISA binding.  
(B) The amino acid sequence of selected clones from the v1.10 mutagenesis library. (c) The amino acid sequence of selected clones from v2.4 mutagenesis library. 
Mutated residues differing from parental sequence are highlighted. See Figure 1 legend for list of abbreviations.
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sDs Page and analytical sec of Final 
Four Purified leads
Post-purification proteins were analyzed by SDS PAGE and 
analytical SEC. On SDS PAGE, the selected clones ran as a single 
band (Figure 5A), with an expected molecular mass of 14 kDa. 
Analytical size-exclusion chromatography of the purified mono-
meric BB10, BA11, BB11, 2G, and E06 control appeared mainly as 
single peaks showing minimal signs of dimerization (Figure 5B) 
unlike the parental clone v1.10 (Figure 2C). The purified BB11 
monomer showed a small peak eluting from the column ahead 
the of the main monomeric protein peak. It is unclear if this is 
dimerized BB11 protein or low level higher molecular weight 
contaminating protein. The remaining humanized VNAR mono-
mers eluted as single peaks.
antigenicity assessment of e06 and Four 
lead humanized Vnar clones
Immunogenicity of lead clones was assessed in a T-cell prolif-
eration assay using ProImmune Ltd REVEAL® Immunogenicity 
System DC–T cell assay. The immunogenicity of each protein was 
determined by measuring the extent of T cells proliferation and 
by determining the number of immune-responsive individual 
FigUre 4 | ELISA and EC50 determination of lead v1.10 and v2.4 humanized E06 clones. Purified E06 His-tagged VNAR protein and selected lead clones were 
added to wells of an human serum albumin-coated plate at a concentration of 1 µg/mL and serially diluted threefold across the plate. Four parameter logistic curve, 
adjustments and EC50 calculations were performed with SigmaPlot 9.0. (a) Binding curves of selected lead clones derived from mutagenesis of the v1.10 backbone. 
(B) Binding curves of selected lead clones derived from mutagenesis of the v2.4 backbone. (c) EC50 values of lead v1.10 derived clones. (D) EC50 values of lead 
v2.4 derived clones. With the exception of E06 v2.4-2G, clones obtained by mutagenesis of E06 v1.10 performed better with several selected clones showing single 
digit nanomolar or lower EC50 values.
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donors treated with test proteins. Stimulation above background 
was determined using flow cytometric evaluation to count 
unlabeled, therefore proliferating T cells in each of the eight rep-
licates for each sample. These values were then used to calculate 
percentage stimulation above background. Thus, the strength 
and frequency of response to each test sample could be used to 
calculate a response index (RI) value for each test protein (E06, 
BB10, BA11, BB11, and 2G) and control antigens (Figures 6B,C). 
Both the wild-type E06 and humanized variants had a very low 
RI compared to positive controls. Of the four humanized leads, 
clone 2G had the highest response. Clone BB11 gave a response, 
which was slightly higher than wild-type E06 with clones BA11 
and BB10 having a slightly lower RI. These RI values were con-
sidered suitable for further development and similar to those of 
other therapeutic antibodies currently in the clinic and assayed 
using an identical protocol. Campath, Avastin, Humira, and 
Remicade had RI values of 0.26, 0.21, 0.14, and 0.49, respectively, 
and control RI values of 4 for KLH and 27.5 for PPD.
Based on this antigenicity assessment, clone 2G was not 
chosen for further study while clones BB10, BA11 BB11, and 
wild-type E06 were reformatted as dimer or trimer genetic 
fusions and expressed with a second control VNAR called 2V. 
Originally isolated from the dogfish Squalus acanthias, 2V is 
part of a sequence database from this species and has no known 
target, making it an ideal control for these and other studies 
(23). When reformatted and expressed as amino or carboxyl 
terminal end dimeric fusion proteins (e.g., 2V-hE06), samples 
ran as single non-aggregated peaks when analyzed by analytical 
SEC (Figure 7A) with the exception of samples BB11-2V and 
2V-BB10 that showed a minor peak eluting before the larger 
main peak, which may indicate the presence of some dimer in 
these samples. When the parental clone v1.10 was reformatted 
as a dimer with 2V, the resultant v1.10-2V protein retained 
its propensity to run as two peaks (Figure 7A). Formatting to 
produce the trimeric versions, 2V-E06-2V, 2V-BA11-2V, and 
2V-BB10-2V also resulted in proteins which after purification 
FigUre 5 | SDS PAGE and analytical SEC analysis of purified lead humanized E06 proteins. (a) Samples of purified humanized VNAR protein analyzed by SDS 
PAGE. Lane M, molecular weight markers; Lane 1, BB10; Lane 2, BA11; Lane 3, BB11; Lane 4, E06 and Lane 5, 2G. (B) Analytical SEC profiles of purified lead 
monomer proteins overlaid and offset to aid comparisons. Profiles are from left to right: BB10, BA11, BB11, E06, and 2G. Data from both analytical techniques 
confirms that proteins tested appear to be monomeric in nature.
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ran predominantly as single peaks (Figure  7B) with BB11 
containing trimeric construct, 2V-BB11-2V, showing a minor 
peak which eluted from the SEC column before the main peak. 
SDS PAGE analysis of monomer BA11, dimers 2V-BA11 and 
BA11-2V, and trimer 2V-BA11-2V confirmed that all migrated 
as single bands with significantly improved biophysical proper-
ties (Figure 7C).
affinity Measurements
Affinity measurements of purified anti-HSA VNAR and human-
ized VNAR monomers E06, 2G, BA11, BB11, and BB10 were 
determined by surface plasmon resonance using a T200 BIAcore 
instrument. The affinities for HSA, presented as a kinetic distri-
bution plot (6A), were in the range of 0.58–24.9 nM. Affinities 
for rat and MSAs were in the range of 2.74–130 and 2.01–99 nM, 
respectively (Figure 6A). For all species tested, wild-type E06 had 
the highest affinity. The loss of binding of clone BB10 to rodent 
albumin could be attributed to the mutation in CDR3 and was 
therefore not taken forward as a candidate for further study. 
The eight dimeric constructs (BB11-2V, 2V-BB11, BB10-2V, 
2V-BB10, BA11-2V, 2V-BA11, E06-2V, and 2V-E06) and four 
trimeric constructs (2V-BB11-2V, 2V-E06-2V, 2V-BA11-2V, and 
2V-BB10-2V) bound HSA with high affinity including low pico-
molar values, 0.08–8.41 nM. In addition, binding and affinities 
for rat, mouse, and cynomolgus macaque albumins confirmed 
the utility of BB11 and BA11 as possible candidates for further 
clinical development (Figure 8).
rat PK Profile and half-life Determination 
of candidate clones
A previous PK study, in three animal species, demonstrated the 
ability of an albumin binding wild-type VNAR domain, E06, 
to extend the half-life of other proteins when administered as a 
molecular fusion (23). The present study looked at the ability of 
the humanized versions of E06, BB11, and BA11 to extend the 
circulating half-life of fusion proteins. Trimeric fusion proteins, 
2V-BB11-2V, 2V-E06-2V, and 2V-BA11-2V, were expressed, 
purified, and characterized (Figures 6 and 8) prior to administra-
tion to rats at 1  mg/kg body weight. For this study, the sensi-
tive and quantitative LC–MS techniques developed previously 
(23) were used to detect the presence of the test trimer VNAR 
fusion proteins in plasma samples. Circulating half-lives were 
determined of 11, 15, and 10 h for 2V-E06-2V, 2V-BA11-2V, and 
2V-BB11-2V, respectively (Figure 9). Peptides derived from the 
albumin-binding domains E06, BA11, and BB11 as well as the 
2V VNAR domain were detected, indicating that the domains 
remained stably linked for the duration of the study (results not 
shown).
stability
The robust nature of VNAR monomeric proteins has been well 
documented (16, 32, 33). This robustness is characterized by the 
ability of VNARs to refold and bind cognate antigens after heating 
to high temperatures, up to 100°C, for extended periods of time. In 
this study, the ability of the shark VNAR parental protein E06 and 
candidate humanized variant BA11 were subjected to a challenge 
at both elevated temperatures and extremes of pH. Incubation at 
100°C for 60 min (Figure 10A) resulted in both E06 and BA11 
proteins retaining a high percentage (~80%) of antigen specific 
binding activity. When challenged by incubation at extremes of 
pH for up to 2 weeks, both proteins showed robust stability and 
retained the capacity to bind HSA after neutralization to pH 7.4 
(Figures 10B,C). Only prolonged treatment of BA11 at pH 1.5 
showed any drop off in antigen binding. Humanization of the E06 
VNAR domain appears not to have had any marked detrimental 
or deleterious effect on the ability of the protein to refold correctly 
after denaturing challenge.
FigUre 6 | Affinity measurement and antigenicity assessment of lead humanized VNAR albumin binding domains. (a) Kinetic distribution plot and BIAcore affinity 
values for purified monomeric proteins E06, BB10, BA11, BB11 and 2G specific for human serum albumin, rat serum albumin, and mouse serum albumin. Values 
are the average of at least two experimental runs. (B) Proliferative T-cell response used to assess immunogenicity of monomeric E06, BB10, BA11, BB11, and 2G.  
(c) Table of calculated response index values. Positive control antigens used for the assay were (i) Tuberculin purified protein derivative (PPD from Mycobacterium) at 
a final assay concentration of 5 µg/mL (70–100% of donors are expected to react to this protein) and (ii) keyhole limpet hemocyanin, a recognized highly 
immunogenic protein.
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DiscUssiOn
The utility of proteins as therapeutic agents is often compromised 
by their biophysical or biochemical properties which can lead to 
downstream processing issues including a propensity to precipi-
tate or aggregate during purification and/or subsequent storage. 
Even if bio-processing is not an issue then a predisposition to elicit 
an adverse or immune response in vivo may also prevent further 
rapid development (34–36). While in silico modeling of VNAR 
domains predicts a low level of immunogenicity with similar 
values for those seen for a human Fc region (results not shown), 
we still embarked on a humanization strategy to accommodate 
any possible concerns from regulators. Immunogenicity testing 
of the parental E06 domain (Figure 6B) did in fact confirm these 
original in silico predictions. Earlier published efforts to human-
ize the HSA-binding, VNAR domain, E06 (24) produced a lead 
clone hE06v1.10, which unfortunately spontaneously dimerized 
(see Figure  1). A further version of humanized E06, based on 
human germline Kappa sequence DPK24, was also assessed, 
and although it was monomeric in solution and expressed 
well in recombinant systems, it unfortunately showed a greatly 
reduced affinity for target antigen. In an effort to improve these 
characteristics, both these humanized versions were subjected to 
a program of random mutagenesis (using error-prone PCR) and 
functional screening.
A panel of 15 clones (Figures 3B,C), demonstrating slow-off 
rates and strong ELISA binding, were chosen for further study 
and sequenced. Monomeric proteins for these clones were pro-
duced by transient expression in HEK 293 cells and EC50 values 
determined (Figures 4C,D). Clones BA11, BB11, BB10, and 2G 
emerged as the preferred “leads.” Only the EC50 values of clones 
generated by mutation of hE06v1.10 were close to the values 
of the starting HuE06v1.10 and E06 (picomolar range). The 
2G clone however saw the greatest improvement in binding to 
1.2 nM from a parental hE06v2.4 EC50 value of 171 nM (also con-
firmed by BIAcore). This 2G clone also had the greatest number 
FigUre 7 | Analytical SEC and SDS PAGE analysis of purified lead humanized proteins reformatted as dimers and trimers. Purification and characterization of 
fusion proteins (a) Analytical SEC chromatograms of dimeric constructs, v1.10-2V, BB11-2V, 2V-BB11, BB10-2V, 2V-BB10, BA11-2V, 2V-BA11, E06-2V, and 
2V-E06 overlaid and offset to aid comparisons. Note: The v1.10-2V protein elutes with two distinct peaks demonstrating the dimerization propensity seen originally 
with the monomeric v1.10 parental clone (Figure 2c). (B) Analytical SEC analysis of the trimeric constructs 2V-BB11-2V, 2V-E06-2V, 2V-BA11-2V, and 2V-BB10-2V. 
Chromatograms show trimeric proteins running as a single peak. (c) SDS PAGE analysis and Coomassie blue staining of approximately 5 µg of purified lead 
humanized protein BA11 as monomer and multimers. Lane M, Thermo Scientific Spectra Broad Range Protein Ladder; Lane 1, monomeric BA11; Lane 2, 
2V-BA11; Lane 3, BA11-2V; Lane 4, 2V-BA11-2V.
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of amino acid changes (4), although it is unclear from this work 
whether the improvement is the result of a single change or the 
four changes in concert.
Binding kinetics of the monomeric anti-HSA clones E06, 
BA11, BB11, BB10, and 2G was measured by surface plasmon 
resonance. The affinity of E06 was determined as 0.58 nM and 
that of huE06v1.10 at 6.4 nM (24). The affinities of the candidate 
humanized and mutated clones all fell within this range. For 
accelerated clinical development of the humanized clones, it is 
also important that they have retained the animal species cross-
reactivity of E06 with comparable affinities. BA11, BB11, and 
2G bound rat and MSAs with affinities between 2 and 130 nM. 
Interestingly, monomeric BB10 was no longer able to bind rodent 
albumin. This is due to the substitution of an isoleucine residue 
at position 90 in CDR3 with a larger hydrophobic phenylalanine 
residue. This hypothesis is supported by the published crystal 
structure (24) as isoleucine 90 contributes to hydrophobic inter-
molecular bonding between huE06 v1.10 and HSA. This lack of 
species cross-reactivity precluded BB10’s use as a candidate clone 
for future clinical development.
Analysis of a larger number of mutated sequences from both 
libraries, performed as a part of their quality control, revealed that 
multiple changes of up to four amino acid positions were observed 
(data not shown). The four lead clones had a change in CDR3, 
indeed in clones BB10 and BB11, this was the only region where a 
change of residue occurs. For BB11, the glycine at position 87 was 
replaced by an alanine residue. BA11 also has a change at position 
87 to a serine and also at position 78 where a phenylalanine is 
replaced by a serine. Clone 2G, which comes from the v2.4 back-
ground, has four mutations from the parental v2.4: asparagine 45 
to a lysine, serine 52 to a glycine, leucine 73 to a methionine and 
a change in CDR3 where glycine 87 is mutated to a serine. The 
result of these mutations was a recovery of binding affinity but 
may have also contributed to the increased immunogenicity seen 
for this clone (Figure 6). Interestingly, clones 1H and 5F, from 
the v2.4 background, both had a substitution at position 88 from 
a valine to an alanine. Clone 5F also had a mutation at position 
63 in HV4 from a threonine to an asparagine. Previous work has 
noted that although containing no contact residues, the HV4 
region of E06 contributed to the binding of albumin by packing 
FigUre 9 | Rat pharmacokinetic (PK) profile and half-life determination of lead trimeric proteins. PK of trimeric VNAR constructs, 2V-BA11-2V, 2V-BB11-2V, and 
2V-E06-2V domains delivered into Sprague Dawley rats via intravenous administration. (a) Graphical representation – mean data from four animals per group.  
(B) Calculated half-lives of administered trimeric proteins. Trimeric protein 2V-BB10-2V was not used in this study due to its loss of binding to rat serum albumin.
FigUre 8 | Affinity measurement of monomeric and reformatted dimeric and 
trimer humanized VNAR lead clones. BIAcore analyses of E06-2V, 2V-E06, 
2V-E06-2V, BB10-2V, 2V-BB10, 2V-BB10-2V, BB11-2V, 2V-BB11, 
2V-BB11-2V, 2V-BA11, BA11-2V, and 2V-BA11-2V against serum albumin 
from different species, human serum albumin, cynomolgus serum albumin, 
mouse serum albumin, and rat serum albumin, using a BIAcore instrument as 
described in the methods section. Kinetic measurements are summarized as 
averages from multiple runs.
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against contact residues of CDR1 (24). This second mutation in 
the HV4 region of clone 5F may explain the improvement noted 
in EC50 values, which decreased from 82 nM (1H) to 18 nM (5F) 
and supports the theory that HV4 packs against the CDR1 region, 
thereby positioning amino acid residues of the CDR1 loop in con-
tact with albumin. The highly selected change of CDR3 residue 87 
(BB11, BA11, and 2G) is not an antigen specific contact residue 
(24), and therefore, retention of binding specificity and affinity 
is unsurprising. However, it does appear that a change at this 
position (or close by at position 90 for BB10) has resolved the 
dimerization bio-processing issue identified as a problem in the 
parental backbone v1.10 (Figure 2). While this phenomenon has 
been seen previously in antibody CDR regions, where particular 
motifs contribute to the multimerization of antibody proteins in 
solution (37, 38), we were surprised that such a small change from 
a glycine to a serine or even alanine could result in the dramatic 
improvement in manufacturability of the expressed protein.
Human immune response to bio-therapeutic proteins is 
notoriously difficult to predict and varies from individual to 
individual. It has been reported that proteins having high homol-
ogy with human proteins or humanized proteins have reduced 
immunogenicity (35), but this cannot simply be presumed to 
be the case. No assay is capable of definitively predicting in vivo 
antigenicity with the only real test being observations from “in 
human” clinical studies (35). However, in vitro testing combined 
with bench-marking against existing clinical assets can provide a 
reasonable level of comfort when selecting candidate molecules 
for costly late stage pre-clinical studies. Humanized E06 VNAR 
domains BA11, BB11, BB10, and 2G showed very low RI values in 
a human donor T-cell proliferation assay using ProImmune Ltd. 
REVEAL® Immunogenicity System DC–T cell assay. Importantly, 
the RI values were comparable to those obtained when Campath, 
Avastin, Humira, and Remicade were investigated using the 
same assay. In fact, when control values are also compared, the 
humanized VNAR, BB10, had a relative RI slightly below those 
determined for this panel of well-known clinical agents and 
chosen lead BA11 has a lower RI than Remicade and is similar to 
humanized antibodies Campath and Avastin.
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FigUre 10 | pH and thermo-stability. Stability analysis of the clones “parental” E06 and “candidate” BA11 to thermal and pH denaturation. (a) Residual antigen-
binding activity was compared to a non-treated time zero control after test proteins were incubated at 100°C for 60 min. The data shown are the average of multiple 
replicates and a typical data set from 2 repeated experiments. (B,c) Residual antigen-binding activity following exposure of test proteins to a range of pH conditions 
for 14 days shown for E06 (B) and BA11 (c).
Based on a combination of affinity, antigenicity, species cross-
reactivity, and expressability, BA11 and BB11 (together with E06 
and BB10 controls) were reformatted as dimeric and trimeric 
fusion proteins using a naive control VNAR 2V. By SDS PAGE, 
these proteins migrated as single bands with predicted molecu-
lar masses (Figure  7C) and confirmed that the bio-processing 
and affinity improvements seen for the monomeric humanized 
mutants was retained when they were assembled in a more 
relevant therapeutic format (fusions at the carboxyl terminal, 
amino terminal fusion, or both). Indeed 2V-BA11 protein was 
concentrated in PBS to therapeutic levels of over 50  mg/mL 
without precipitation, a favorable property for drug formulation, 
and retained a single-peak, SEC profile (data not shown).
Albumin half-life in the systemic circulation is prolonged 
by the FcRn recycling process (39, 40). In an early publication, 
monomeric and multimeric VNAR constructs containing the 
wild-type E06 albumin-binding domain showed a very impres-
sive extended half-life equivalent to that of the species-specific 
(rodent or non-human primates) serum albumin (23). In this 
study, the functional ability of the humanized albumin-binding 
domains BA11 and BB11 and the wild-type E06 to extend circu-
lating half-life, formatted as fusion proteins with the 2V VNAR 
domain (as trimers), was examined in a suitable rodent model. 
The humanized variants had a half-life (2V-BA11-2V 15 h and 
2V-BB11-2V 10 h) equivalent to the parental control (2V-E06-2V 
11 h), thereby confirming that the humanized domains remained 
bound to RSA during the FcRn recycling process.
Based on the accumulated data from affinity, analytical SEC 
profile, expressability, protein bio-processing quality, immuno-
genicity, and rodent-half-life studies, BA11 emerged as the clear 
candidate molecule for further study. To avoid confusion, it is 
worth noting that recent commercial literature often refers to 
humanized VNAR as soloMERs™ (22) and BA11 as NDure™.
Single-domain antibodies from shark (16, 32, 33) and camelid 
(41–43) species have an ability to refold and bind antigen after 
thermal and chemical denaturation. Here, the candidate clone 
BA11 was subjected to extreme thermal and pH challenge. Both 
the monomeric wild-type E06 and candidate clone showed a 
remarkable ability to bind cognate antigen after temperature or 
pH induced unfolding, confirming that functional binding and 
surprisingly functional stability (which had been ignored as part 
of clone “culling”) had been retained through the mutation and 
selection process.
Naturally occurring protein binding domains with the 
potential for development as bio-therapeutic drugs are being 
investigated many research and development laboratories of the 
pharmaceutical industry. In this article, we have detailed the 
successful humanization of an albumin binding domain isolated 
from shark VNAR library. This domain, E06, was humanized 
in a manner that facilitated the retention of high affinity and 
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